Literature DB >> 10972542

Inositol 1,4,5-trisphosphate and reperfusion arrhythmias.

E A Woodcock1, J F Arthur, S J Matkovich.   

Abstract

1. The present review focuses on the role of the Ca2+-releasing second messenger inositol 1,4,5-trisphosphate (IP3) in initiating arrhythmias during early reperfusion following a period of myocardial ischaemia. 2. Evidence for an arrhythmogenic action of IP3 was provided by studies showing a correlation between the extent of the increase in IP3 and the incidence of arrhythmias in early reperfusion. In addition, phospholipase C inhibitors selective for thrombin receptor stimulation were anti-arrhythmic only when arrhythmias were thrombin initiated. 3. Mechanisms by which IP3 could initiate arrhythmias are discussed, with particular emphasis on the role of slow and unscheduled Ca2+ release. 4. The reperfusion-induced IP3 and arrhythmogenic responses can be initiated through either alpha1-adrenoceptors or thrombin receptors, but endothelin receptor stimulation was ineffective. Further studies have provided evidence that the noradrenaline-mediated response was mediated by alpha1A-receptors, while the alpha1B-adrenoceptor subtype appeared to be protective. 5. Reperfusion-induced IP3 responses could be inhibited by procedures known to reduce the incidence of arrhythmias under these conditions, including preconditioning, inhibiting Na+/H+ exchange or by dietary supplementation with n-3 polyunsaturated fatty acids. 6. Inositol 1,4,5-trisphosphate generation in cardiomyocytes can be facilitated by raising intracellular Ca2+ and it seems likely that the rise in Ca2+ in ischaemia and reperfusion is responsible for the generation of IP3, which will, in turn, further exacerbate Ca2+ overload.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10972542     DOI: 10.1046/j.1440-1681.2000.03328.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  8 in total

Review 1.  Gene therapy for ventricular tachyarrhythmias.

Authors:  J K Donahue
Journal:  Gene Ther       Date:  2012-04-26       Impact factor: 5.250

Review 2.  Fibrin(ogen) and its fragments in the pathophysiology and treatment of myocardial infarction.

Authors:  Kai Zacharowski; Paula Zacharowski; Sonja Reingruber; Peter Petzelbauer
Journal:  J Mol Med (Berl)       Date:  2006-05-06       Impact factor: 4.599

3.  Role of inositol 1,4,5-trisphosphate in the regulation of ventricular Ca(2+) signaling in intact mouse heart.

Authors:  Ariel L Escobar; Claudia G Perez; Mariano E Reyes; Sarah G Lucero; Dmytro Kornyeyev; Rafael Mejía-Alvarez; Josefina Ramos-Franco
Journal:  J Mol Cell Cardiol       Date:  2012-08-31       Impact factor: 5.000

Review 4.  Emerging roles of inositol 1,4,5-trisphosphate signaling in cardiac myocytes.

Authors:  Jens Kockskämper; Aleksey V Zima; H Llewelyn Roderick; Burkert Pieske; Lothar A Blatter; Martin D Bootman
Journal:  J Mol Cell Cardiol       Date:  2008-06-15       Impact factor: 5.000

5.  Thrombin receptor and ventricular arrhythmias after acute myocardial infarction.

Authors:  Lilong Tang; Chunyu Deng; Ming Long; Anli Tang; Shulin Wu; Yugang Dong; Louis D Saravolatz; Julius M Gardin
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

6.  Inhibition of thromboxane A2-induced arrhythmias and intracellular calcium changes in cardiac myocytes by blockade of the inositol trisphosphate pathway.

Authors:  M J Wacker; L M Kosloski; W J R Gilbert; C D Touchberry; D S Moore; J K Kelly; M Brotto; J A Orr
Journal:  J Pharmacol Exp Ther       Date:  2009-09-09       Impact factor: 4.030

7.  The involvement of TRPC3 channels in sinoatrial arrhythmias.

Authors:  Yue-Kun Ju; Bon Hyang Lee; Sofie Trajanovska; Gouliang Hao; David G Allen; Ming Lei; Mark B Cannell
Journal:  Front Physiol       Date:  2015-03-25       Impact factor: 4.566

Review 8.  Inositol 1,4,5-trisphosphate receptors in cardiomyocyte physiology and disease.

Authors:  Kateryna Demydenko; Samaneh Ekhteraei-Tousi; H Llewelyn Roderick
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2022-10-03       Impact factor: 6.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.